Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study | Synapse
March 16, 2026Open Access
Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study
Key Points
The study aims to evaluate the effectiveness and safety of the anti-EGFR and anti-PD1 combination in advanced cutaneous squamous cell carcinoma.
Cohort study design
Inclusion of heavily pretreated patients
Assessment of clinical activity and safety
The combination treatment showed clinical activity in the population
Safety profile was acceptable for patients undergoing later-line therapy
Abstract
In a heavily pretreated real-life population with advanced cSCC, the anti-PD1/anti-EGFR combination showed clinical activity with acceptable safety, supporting its role as later-line strategy.